-
Uncategorized3 weeks agoSTAT+: Closely watched experimental Parkinson’s drug fails key clinical trial
Biogen and Denali Therapeutics said Thursday that their experimental therapy for Parkinson’s disease failed to slow the degenerative brain disorder in a randomized trial, dealing a...
-
Uncategorized3 weeks agoSTAT+: 3 burning questions senators had for the NIH director
Thursday’s Senate Appropriations Committee hearing was intended to focus on President Trump’s proposed budget for the National Institutes of Health’s fiscal year 2027 budget. Instead, many...
-
Uncategorized3 weeks ago
#ASCO26: Merck partner Kelun outlines Phase 3 lung cancer success in China study
Merck partner Kelun-Biotech fleshed out a Phase 3 win in lung cancer from a study in China for the experimental antibody-drug conjugate sac-TMT, raising hopes that...
-
Uncategorized3 weeks ago
How To Shine As Biotech Comes Back From the Brink
Biotech has been pulling off some remarkable science of late, while M&A and IPOs return to bolster the sector. But that doesn’t mean the industry is...
-
Uncategorized3 weeks agoBio-IT World Celebrates 25 Years with Opening Plenary on Rare Disease Challenges and Opportunities
BOSTON — Thomas Bartlett’s life changed in 2019 when he was diagnosed with late-onset myasthenia gravis (MG). The 15-year veteran of the Bio-IT World Conference and...
-
Uncategorized3 weeks ago
AI Model Offers Map of How Genes Work Together in Different Cellular Contexts
AI Model Offers Map of How Genes Work Together in Different Cellular Contexts
-
Uncategorized3 weeks agoGuarding biotech from China and big bets in longevity
On this week’s episode of “The Readout LOUD,” the hosts discuss STAT’s Breakthrough Summit West, where powerful leaders from health care and science rubbed shoulders. They...
-
Uncategorized3 weeks ago
How a group of biotechs ran a covert campaign to push out the FDA commissioner
Biohaven CEO Vlad Coric finally had the attention of the FDA, and most importantly, Commissioner Marty Makary. In late April, after the company’s spinocerebellar ataxia drug...
-
Uncategorized3 weeks ago
Update: Reversal after 20 deaths allows new Japan patients to take Amgen’s rare disease drug Tavneos
Kissei Pharmaceutical is reversing a recommendation related to Amgen-shared Tavneos that it made just a few days ago, now saying the rare disease drug can be...
-
Uncategorized3 weeks ago
Chutes & Ladders—Former FDA leader takes new biotech Turn
Stephen Hahn, M.D., who served as the commissioner of the FDA for just over a year during the first Trump administration, is taking his extensive regulatory...
Amgen shores up Tavneos’ FDA defense with Duke data analysis
